PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia: A Cross-Sectional Cohort Study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective—: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a downregulator of the low density lipoprotein receptor. The aims of this cross-sectional cohort-study were to examine whether the PCSK9 R46L loss of function variant found in a cohort of familial hypercholesterolemia (FH) patients was associated with lower low density lipoprotein cholesterol, lower frequency of xanthomata, and cardiovascular risk. Approach and Results—: We studied FH patients attending the IRCM (Institut de Recherches Cliniques de Montréal) Lipid Clinic and whose DNA genotyping was positive for a low density lipoprotein receptor mutation. The presence of the PCSK9 loss of function R46L missense variant was determined among a cohort of 582 FH patients by genotyping. Frequency of the R46L variant was 3%. Carriers had significantly lower low density lipoprotein cholesterol (11%, P =0.002), total cholesterol (9%, P =0.007), apolipoprotein B (10%, P =0.037), and non-high density lipoprotein (12%, P <0.001) concentrations compared with noncarriers. Furthermore, R46L carriers showed a decreased average number of xanthoma per individual compared with noncarriers (0.33 and 0.76, respectively; P <0.001). Importantly, the R46L genetic variant was associated with a significant 86% lower odd of presenting a cardiovascular event (odds ratio, 0.14; 95% confidence interval, 0.032–0.63; P =0.001). Conclusions—: Even though the R46L variant was present in 3% of our FH population, carriers of this polymorphism showed attenuated effect of the low density lipoprotein receptor mutation on parameters, such as low density lipoprotein cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. More importantly, this mutation is associated with a significant lower risk of cardiovascular disease compared with noncarriers. It is therefore likely that targeting PCSK9 in FH patients with novel anti-PCSK9 therapies will be useful in reducing cardiovascular risk in affected subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor System
Goldstein, J. L., Brown, M. S., Anderson, R. G. W., Russell, D. W., & Schneider, W. J. (1985) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.01.110185.000245 · Cited by 1,600
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 1×
“Clinical studies in non-FH populations showed that carriers of heterozygous LOF polymorphisms in PCSK9 were associated with a 15% to 49% reduction in LDL-C levels compared with noncarriers.(7,8) Among the PCSK9 LOF variants, R46L is the most common occurring in exon 1 of the PCSK9 gene, affecting ≈1/50 individuals, wi…”
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517 · cited 1×
“Clinical studies in non-FH populations showed that carriers of heterozygous LOF polymorphisms in PCSK9 were associated with a 15% to 49% reduction in LDL-C levels compared with noncarriers.(7,8) Among the PCSK9 LOF variants, R46L is the most common occurring in exon 1 of the PCSK9 gene, affecting ≈1/50 individuals, wi…”
Lambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236 · cited 2×
“Nevertheless, a previous report observed that compound carriers of the PCSK9 R46L variation and of a LDLR mutation associated with FH responded much better to statin therapy compared with controls.(25) A decade of scientific research on PCSK9 resulted in the development of neutralizing molecules, such as monoclonal an…”
Cited by
Clinical Genetic Testing for Familial Hypercholesterolemia
Sturm, A. C., Knowles, J. W., Gidding, S. S., Ahmad, Z. S., Ahmed, C. D., Ballantyne, C. M., Baum, S. J., Bourbon, M., Carrié, A., Cuchel, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.044 · Cited by 615
The complex molecular genetics of familial hypercholesterolaemia
Berberich, A. J., & Hegele, R. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0052-6 · Cited by 290
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz, R., Schlüter, K.-D., & Laufs, U. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0463-z · Cited by 137
Paquette, M., Chong, M., Thériault, S., Dufour, R., Paré, G., & Baass, A. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.03.019 · Cited by 115
Self-citationComplexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Dron, J. S., & Hegele, R. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000386 · Cited by 72
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“During insulin resistance, dysregulation of lipid and cholesterol metabolism leads to CVD. Insulin resistance is correlated with high cholesterol synthesis and decreased cholesterol absorption in men (254).”
InfluentialLoss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Self-citation
Metadata
- Authors
- Luna Saavedra, Y. G., Dufour, R., Davignon, J., & Baass, A.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2014-12
- Volume
- 34
- Issue
- 12
- Pages
- 2700-2705
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2523564199
- Cited by
- 77
- References
- 11
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.